Page last updated: 2024-10-15

7,8-dihydropterin

Description

7,8-dihydropterin: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135440520
CHEMBL ID3278662
CHEBI ID137235
CHEBI ID193164
SCHEMBL ID676634
SCHEMBL ID10541653
MeSH IDM0085115

Synonyms (16)

Synonym
7,8-dihydropterin
dihydropterin
h2-pterin
CHEBI:137235
2-amino-7,8-dihydro-1h-pteridin-4-one
CHEBI:193164
4(1h)-pteridinone, 2-amino-7,8-dihydro-
2-amino-4-oxo-3,4,7,8-tetrahydropteridine
17838-80-1
BACTERIAL DIHYDROPTERIN 1112
CHEMBL3278662
SCHEMBL676634
SCHEMBL10541653
2-amino-7,8-dihydro-3h-pteridin-4-one
DTXSID70170466
2-amino-7,8-dihydro-4-hydroxypteridine
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
pterins
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1146850Inhibition of Escherichia coli dihydroneopterin aldolase assessed as [14C]glycolaldehyde formation using [14C]neopterin substrate by scintillation counting1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Inhibitors of folate biosynthesis. 1. Inhibition of dihydroneopterin aldolase by pteridine derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (33.33)18.7374
1990's1 (8.33)18.2507
2000's6 (50.00)29.6817
2010's1 (8.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]